Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results